What have we learned? All put together, results of ALDO-DHF -while being very interesting from a mechanistic point of view -are unlikely to change clinical practice significantly given the lack of symptomatic improvement and potentially serious side effects associated with the use of spironolactone. At this stage, spironolactone can only be recommended as a third-or fourth-line antihypertensive agent in patients with HFpEF who have not achieved target blood pressures, and with close monitoring of renal function and serum potassium levels. More insight into the clinical value of spironolactone in HFpEF should be provided next year by the results of the Treatment of Preserved Cardiac Function Heart Failure (TOPCAT) study [4] .
PARAMOUNT -THE NEW KID ON THE BLOCK
Results of another trial addressing treatment of HFpEF -The Prospective compArison of angiotensin Receptor/neprilysin inhibitor with Angiotensin receptor blocker on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial -were also presented at the European Society of Cardiology meeting in Munich [5, 6] .
PARAMOUNT was a phase II multicenter trial conducted in 13 countries that randomized 308 patients (mean age ¼ 71 years with 57% being women) with a documented history of heart failure, ejection fraction of $ 45% and NT-proBNP $ 400 pg/ml) to either the angiotensin receptor blocker valsartan or to the novel angiotensin receptor/neprilysin inhibitor (ARNI) -currently known as LCZ696. This first-in-class drug is a dual-acting neprilysin inhibitor and angiotensin receptor blocker as it comprises the molecular moieties of both AHU337 and valsartan. Neprilysin is an endopeptidase that degrades the biologically active natriutetic peptides including atrial natriuretic peptide (ANP), brain-type natriuretic peptide (BNP) and C-type natriuretic peptide. The biologically inert NT-proBNP is not a substrate of this enzyme and is therefore unaffected by its inhibition i.e. changes in circulating levels reflect true changes in left ventricular wall stress [7] . Natriuretic peptides have potent vasodilator and diuretic properties, reduce sympathetic drive, and have antiproliferative and antifibrotic effects. They also enhance myocardial relaxation via increasing the generation of cardiac cyclic guanosine monophosphate (cGMP) [8] . Neprilysin is however also involved in the breakdown of angiotensin II, hence the rationale for using dual-acting agents that combine neprilysin inhibition with angiotensin receptor blockage. The primary end-point was change from baseline NT-proBNP assessed at 12 weeks. Secondary end-points included changes in left ventricular volumes, ejection fraction, left atrial volume and echocardiographic parameters of diastolic function as well as NYHA class and quality of life (Kansas City Cardiomyopathy Questionnaire). The investigators postulated that cardiac structural changes will need more time to manifest, hence chose to assess them at 36 weeks.
At 12 weeks, change in NT-proBNP levels from baseline was significantly different in the LCZ696 group compared with the valsartan group (ratio of change LCZ696/valsartan 0.77, 95% CI 0.64 -0.92, p ¼ 0.005) with a greater reduction seen in the LCZ696 arm -a finding that remained significant after adjusting for changes in blood pressure. Prespecified subgroups analysis broke patients out by age, systolic blood pressure, atrial fibrillation, renal function and diabetes. The beneficial effect of LCZ696 on NT-proBNP remained statistically significant amongst each of these subgroups; however, it appeared to be more striking in diabetic patients. At 36 weeks, the difference between NT-proBNP levels in both groups was no longer significant ( p ¼ 0.20). Left atrial volumea powerful prognostic indicator in patients with heart failure and an accurate marker of the chronicity of elevated left ventricular filling pressures -was significantly reduced in the LCZ696 group ( p ¼ 0.003). All other echocardiographic measurements did not differ between both treatment groups. Improvement in NYHA class (but not quality of life) was noted at 36 weeks in the LCZ696 group compared to the valsartan group. The number of patients with hypotension, renal dysfunction or hyperkalemia did not differ between groups. Estimated glomerular filtration rate (eGFR) decreased to a greater extent in the valsartan group (LCZ696, 21.6 mL/min per 1.73 m2 vs valsartan, 2 5.2 mL/min per 1.73 m2; p ¼ 0.007) and urinary albumin:creatinine ratio increased to a greater extent in the LCZ696 group (LCZ696, 1.9 mg/mmol at baseline, 2.9 mg/mmol at week 36; valsartan, 2.0 mg/mmol at baseline, 2.0 mg/mmol at week 36; p ¼ 0.02). Adverse events did not differ significantly between both treatment groups; the study was not however designed to test clinical outcomes [6] .
